LITERATURE SEARCH STRATEGY

Warning: The NCBI web site requires JavaScript to function. more...

NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.

Saxagliptin (Onglyza): Indicated in Patients with Type 2 Diabetes Mellitus to Improve Glycemic Control in Combination with Metformin and a Sulfonylurea when Dual Therapy with these Two Agents, with Diet and Exercise, does not Provide Adequate Glycemic Control [Internet]. Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2013 Nov.

Saxagliptin (Onglyza): Indicated in Patients with Type 2 Diabetes Mellitus to Improve Glycemic Control in Combination with Metformin and a Sulfonylurea when Dual Therapy with these Two Agents, with Diet and Exercise, does not Provide Adequate Glycemic Control [Internet].

Show details

Contents

< Prev Next >

APPENDIX 2LITERATURE SEARCH STRATEGY

OVERVIEW
Interface:	Ovid
Databases:	Embase 1974 to present MEDLINE Daily and MEDLINE 1946 to present MEDLINE In-Process & Other Non-Indexed Citations Note: Subject headings have been customized for each database. Duplicates between databases were removed in Ovid.
Date of Search:	June 25, 2013
Alerts:	Weekly search updates until October 16, 2013
Study Types:	No search filters were applied
Limits:	Date limit: 2012 to present No language limits were used. Conference abstracts were excluded.
SYNTAX GUIDE
/	At the end of a phrase, searches the phrase as a subject heading
.sh	At the end of a phrase, searches the phrase as a subject heading
*	Before a word, indicates that the marked subject heading is a primary topic; or, after a word, a truncation symbol (wildcard) to retrieve plurals or varying endings
adj	Requires words that are adjacent to each other (in any order)
.ti	Title
.ab	Abstract
.hw	Heading Word; usually includes subject headings and controlled vocabulary
.nm	Name of Substance Word
.ot	Original title
.pt	Publication type
.rn	CAS registry number
pmez	Ovid database code; MEDLINE In-Process & Other Non-Indexed Citations, MEDLINE Daily and Ovid MEDLINE 1946 to Present
oemezd	Ovid database code; Embase 1974 to present, updated daily

MULTI-DATABASE STRATEGY
1	(onglyza* or saxagliptin* or bms477118 or (bms adj "477118")).ti,ot,ab,sh,rn,hw,nm.
2	945667-22-1.rn,nm.
3	1 or 2
4	3 use pmez
5	*saxagliptin/
6	(onglyza* or saxagliptin* or bms477118 or (bms adj "477118")).ti,ab.
7	5 or 6
8	7 not conference abstract.pt.
9	8 use oemezd
10	4 or 9
11	remove duplicates from 10
12	limit 11 to yr="2012 -Current"

OTHER DATABASES
PubMed	Same MeSH, keywords, limits, and study types used as per MEDLINE search, with appropriate syntax used.
Trial registries (Clinicaltrials.gov and other)	Same keywords, limits used as per MEDLINE search.

Grey Literature

Dates of Search:	July 17, 2013
Keywords:	saxagliptin (Onglyza), Diabetes mellitus, type 2
Limits:	Date: January 2012 to present, no language limits used

Relevant websites from the following sections of the CADTH grey literature checklist, “Grey matters: a practical tool for evidence-based searching” (http://www.cadth.ca/en/resources/finding-evidence-is/grey-matters) were searched:

Health Technology Assessment Agencies
Health Economics
Drug and Device Regulatory Approvals
Advisories and Warnings
Databases (free).

You are permitted to make copies of this document for non-commercial purposes, provided it is not modified when reproduced and appropriate credit is given to CADTH. You may not otherwise copy, modify, translate, post on a website, store electronically, republish, or redistribute any material from this document in any form or by any means without the prior written permission of CADTH.

Please contact CADTH’s Vice-President of Corporate Services at ac.htdac@secivresetaroproc with any inquiries about this notice or other legal matters relating to CADTH’s services.

Except where otherwise noted, this work is distributed under the terms of a Creative Commons Attribution-NonCommercial- NoDerivatives 4.0 International licence (CC BY-NC-ND), a copy of which is available at http://creativecommons.org/licenses/by-nc-nd/4.0/

Bookshelf ID: NBK195490

Contents

< Prev Next >

PubReader
Print View
Cite this Page
Saxagliptin (Onglyza): Indicated in Patients with Type 2 Diabetes Mellitus to Improve Glycemic Control in Combination with Metformin and a Sulfonylurea when Dual Therapy with these Two Agents, with Diet and Exercise, does not Provide Adequate Glycemic Control [Internet]. Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2013 Nov. APPENDIX 2, LITERATURE SEARCH STRATEGY.